CHAIRMAN OF THE BOARD
Dr. Reinhard Ambros has held international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. From 2005 through 2017, Reinhard developed and led the Novartis Venture Fund to become one of the largest corporate biotechnology venture funds in the life sciences industry. Previously, he served as head of group strategic planning and BD&L for cardiovascular and metabolic diseases for Novartis Corporation and Novartis Pharma AG, respectively. Reinhard serves on the boards of public and private biotechnology companies in Europe and the United States, and as an advisor to German and Swiss Government Biotechnology Funds.
VICE CHAIRMAN
Dr. Daniel Vasella served as Chairman of Novartis AG, a leading global medicines company, from 1999 until 2013 and as Chief Executive Officer of Novartis from 1996 to 2010. Previously, Daniel held the positions of Chief Executive Officer, Chief Operating Officer, Senior Vice President, Head of Worldwide Development, and Head of Corporate Marketing at Sandoz Pharma Ltd. He currently is currently working as a director, strategic advisor, and coach to senior executives, and serves on the boards of PepsiCo, American Express Company, SciClone Pharmaceuticals, and several biotech companies.
DIRECTOR
Dr. Michael Baran is Executive Director, Pfizer Worldwide Research and Development and a Partner at Pfizer Ventures, where he is responsible for identifying, evaluating, making and managing equity investments aligned with the strategy of Pfizer. Prior to his current position, Mike held roles in R&D portfolio strategy as well as managing scientific affairs for the R&D President’s office at Pfizer. Mike joined Pfizer from Nexomics Biosciences, a structural biology biotech company which he co-founded. He previously worked within the NIH Protein Structure Initiative’s Northeast Structural Genomics Consortium coordinating protein structure production efforts.
DIRECTOR
Dr. Markus Hosang is a General Partner of BioMedPartners AG. Before joining BioMedPartners, Markus was a Venture Partner at MPM Capital, where he was co-responsible for European deal flow, managed MPM’s European office in Munich, and served on the boards of several portfolio companies. Prior to joining MPM, Markus was at Roche, where he served for nearly 20 years in several senior management positions in the Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D.
DIRECTOR
Dr. Andreas Jurgeit is a Partner with the life science team of GIMV, a publicly listed (Euronext:GIMV) private equity and venture capital investor.
Previously, Andreas worked with the venture capital arm of Lundbeckfonden and at Merck Ventures where he was responsible for investments and company creation in Europe, the United States, and Israel. Andreas started his career at Redalpine Venture Partners and has operational experience in drug discovery, business development, and M&A.
DIRECTOR
Steve Tregay, PhD is a Managing General Partner at Mission BioCapital based in Cambridge. He focuses on new therapeutics investments with a particular emphasis on company creation opportunities as well as on overall management of the firm. Within the Mission BioCapital portfolio, he is currently founding CEO and board member of Arclight Therapeutics, LLC, a founding board member at Jupiter BioVentures LLC, and has board roles at Vedere Bio and NocionTherapeutics. In addition, Steve serves as Chairman of the Board of Directors at LabCentral. He is a Harvard Blavatnik Biomedical Accelerator Advisory Committee member and is a member of the board of advisors for the non-profit Life Sciences Cares.
Previously, Steve was the Founder and CEO of FORMA Therapeutics. Additional roles held prior to his engagement at FORMA include Managing Director for the Novartis Venture Fund and Executive Director & Head of Strategic Alliances for Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. Prior to Novartis, he held roles in research and business development at Array BioPharma.
Steve received his doctoral and Master’s degree in organic chemistry from Harvard University and a Bachelor’s from Davidson College.